Journal of Contemporary Pharmacy Practice最新文献_第8页

Extended Reality in Patient Care and Pharmacy Practice: A Viewpoint 扩展现实在病人护理和药学实践:一个观点

Journal of Contemporary Pharmacy Practice Pub Date : 2019-12-01 DOI: 10.37901/jcphp18-00030

Jody K. Takemoto, Brittany L. Parmentier, Rachel Bratelli, Thayer A. Merritt

引用次数: 1

State and National Organizations Supporting the Profession of Pharmacy 支持药学专业的州和国家组织

Journal of Contemporary Pharmacy Practice Pub Date : 2019-09-01 DOI: 10.37901/jcphp19-00ee3

Jon Roth

引用次数: 0

Critical Appraisal of the ASCEND Trial 对ASCEND试验的批判性评价

Journal of Contemporary Pharmacy Practice Pub Date : 2019-09-01 DOI: 10.37901/jcphp18-00031

Aya F. Ozaki, C. Jackevicius

引用次数: 0

Focus on New Diabetes Treatment Options with Cardiovascular Benefits 关注具有心血管益处的新型糖尿病治疗方案

Journal of Contemporary Pharmacy Practice Pub Date : 2019-09-01 DOI: 10.37901/jcphp18-00029

Jeany Kim Jun

{"title":"Focus on New Diabetes Treatment Options with Cardiovascular Benefits","authors":"Jeany Kim Jun","doi":"10.37901/jcphp18-00029","DOIUrl":"https://doi.org/10.37901/jcphp18-00029","url":null,"abstract":"The landscape of diabetes treatment options has changed due to new diabetes drug approvals, changes in the Food and Drug Administration indications based on cardiovascular (CV) outcomes studies, as well as the approval of follow-on biologic insulins. Two new drugs were approved for type 2 diabetes mellitus including ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and semaglutide, a glucagon-like peptide-1 (GLP1) receptor agonist joining a number of other drugs in these classes. In addition, follow-on biologic insulins, such as long-acting Basaglar (insulin glargine), and rapid-acting insulins Admelog (insulin lispro) and Fiasp (insulin aspart), were also approved. Furthermore, the CV outcome trial for dapagliflozin was published in November 2018 showing CV benefits. Finally, the 2018 joint American Diabetes Association (ADA) and European Association for the Study of Diabetes statement on the management of type 2 diabetes and the 2019 ADA Standards of Care for Diabetes made several recommendations. They encourage the use of agents with CV benefit in those with established atherosclerotic cardiovascular disease (ASCVD) or heart failure and to consider GLP1 receptor agonists as the first injectable agent, even before basal insulin, in certain patients. The purpose of this review is to discuss recently approved agents for type 2 diabetes comparing the available cardiovascular findings of SGLT2 inhibitors and GLP1 receptor agonists and outline key take-home points when recommending additional treatment for patients with type 2 diabetes after metformin.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47235243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Blood Cholesterol to Reduce Atheroscelerotic Cardiovascular Risk in Adults 治疗血胆固醇降低成人动脉粥样硬化心血管风险

Journal of Contemporary Pharmacy Practice Pub Date : 2019-09-01 DOI: 10.37901/jcphp18-00004

Cori Gray, C. Stern

{"title":"Treatment of Blood Cholesterol to Reduce Atheroscelerotic Cardiovascular Risk in Adults","authors":"Cori Gray, C. Stern","doi":"10.37901/jcphp18-00004","DOIUrl":"https://doi.org/10.37901/jcphp18-00004","url":null,"abstract":"Cholesterol is a fat-like substance our body needs to build cell membranes, make certain hormones and produce substances that aid in the digestion of fat. Two kinds of lipoproteins carry cholesterol throughout your body: low-density lipoproteins (LDL) and high-density lipoproteins (HDL). LDL cholesterol typically makes up 60–70 percent of the total serum cholesterol in our body and is the primary target of therapy. A high LDL level leads to a buildup of cholesterol in arteries.\u0000\u0000Hyperlipidemia occurs when your blood has too many lipids (or fats), such as cholesterol and triglycerides. Hypercholesterolemia means there is too much LDL (bad) cholesterol in your blood,3 and that increases your risk of developing atherosclerosis, coronary heart disease, stroke, and peripheral vascular disease.2 LDL-cholesterol levels of <100 mg/dL are considered optimal. At near optimal levels, 100–129 mg/dL, atherogenesis, the formation of abnormal fatty or lipid masses in arterial walls, occurs. At borderline high levels, 130–159 mg/dL, atherogenesis proceeds at a significant rate. At high levels, 160–189 mg/dL, and very high levels, ≥190 mg/dL, atherogenesis is accelerated.2\u0000\u0000Two main factors causing hyperlipidemia are lifestyle and genetic predispositions. An inherited condition called familial hypercholesterolemia (FH) causes very high LDL cholesterol.1","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49194599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The Effect of a Tailored Patient Activation Intervention in Inflammatory Bowel Disease Patients 量身定制的患者激活干预在炎症性肠病患者中的作用

Journal of Contemporary Pharmacy Practice Pub Date : 2019-09-01 DOI: 10.37901/jcphp18-00009

Chisom Kanu, Carolyn Brown, J. Barner, C. Chapman, H. Walker

{"title":"The Effect of a Tailored Patient Activation Intervention in Inflammatory Bowel Disease Patients","authors":"Chisom Kanu, Carolyn Brown, J. Barner, C. Chapman, H. Walker","doi":"10.37901/jcphp18-00009","DOIUrl":"https://doi.org/10.37901/jcphp18-00009","url":null,"abstract":"Purpose\u0000\u0000A pre-test, post-test, control group design was employed to investigate the impact of a tailored patient activation intervention (PAI) among inflammatory bowel disease (IBD) patients.\u0000\u0000Methods\u0000\u0000Patients who met the inclusion criteria were selected from medical records via convenience sampling, were consented, and completed a baseline survey. Based on responses to the baseline 13-item patient activation measure (PAM-13), they were categorized into one of four patient activation stages. During office visits, intervention patients (N=23) were given a tailored PAI based on their baseline stage, which consisted of an information booklet and focused discussion with the gastroenterologist, while the control group (N=27) received usual care. Baseline and 1-month post-intervention scores were compared between the intervention (N=20) and control (N=21) groups for changes in patient activation score, medication adherence, and satisfaction with care.\u0000\u0000Results\u0000\u0000Most participants were Caucasian (88%), female (64%), college graduates (56%), and had Crohn's disease (59.2%). Overall, females had a significantly higher (p=0.04) mean activation score (mean=70.9±15.4) than males (mean=60.9±10.7) at baseline. This trend was the same post-intervention (75.6 females vs 64.4 males; p=0.03). The difference in mean activation scores pre- vs post-intervention was not statistically significant between the intervention and control groups (mean=4.9±12.3, p=0.21). However, this difference could be considered to be clinically significant based on results from previous studies. There were no significant differences in medication adherence or satisfaction scores pre- vs post-intervention for either group.\u0000\u0000Conclusion\u0000\u0000Tailored PAIs have the potential to increase activation level of patients with inflammatory bowel disease. This customized medical interaction increased patient involvement in disease management and could potentially lead to improved health outcomes.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43890950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Development and in-vitro characterization of tiropramide tablets having immediate- and extended release layers 具有立即释放层和缓释层的替罗普胺片的研制和体外表征

Journal of Contemporary Pharmacy Practice Pub Date : 2019-07-31 DOI: 10.56770/jcp2019313

Muhammad Riaz, Liaqat Ali, S. Javed, Syed Aatif Hussain, Hassan Haider Shah, Khaleeq Anwer

{"title":"Development and in-vitro characterization of tiropramide tablets having immediate- and extended release layers","authors":"Muhammad Riaz, Liaqat Ali, S. Javed, Syed Aatif Hussain, Hassan Haider Shah, Khaleeq Anwer","doi":"10.56770/jcp2019313","DOIUrl":"https://doi.org/10.56770/jcp2019313","url":null,"abstract":"Purpose: The objective of this study was to explore the feasibility of developing of Tiropramide, bilayer tabletusing an immediate- and extended-release formulation. Method: After rheological performance of drug-excipientsmixture, Tiropramide HCl bilayer tablets were prepared by wet granulation method. FTIR analysis was performed toelucidate the compatibility behavior of drug and excipients. Effect of these varying concentrations of EthylCellulose (EC) and Hydroxy Propyl Methyl Cellulose (HPMC) were observed on the sustained release pattern of thematrices. Dissolution was performed by using 0.1N HCl and phosphate buffer pH 7.2 as medium at 37.0 ±0.5 ºC,while the stirring speed was set at 50RPM. The bilayer tablets were stored under conditions 40±2oC temperature and 75±5% humidity for stability testing. Results: It was observed that as the quantity of polymers (HPMC or EC)increases the sustained release effect also increases. It was obvious from these models that drug release form bilayer tablets followed the zero order model and Higuchi square root model and the drug release mechanism was diffusion and erosion. The polymers-drug combination was compatible in bilayer tablets before and during stability testing. Conclusion: Bilayer tablet of Tiropramide can be developed successfully in which one layer provides immediate release while the other prolongs the drug release.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72911814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Fabrication and characterization of fast dissolving films of H2-receptor antagonist h2受体拮抗剂快溶膜的制备与表征

Journal of Contemporary Pharmacy Practice Pub Date : 2019-07-31 DOI: 10.56770/jcp2019312

Rimsha Iram, Iqra Akram, Bushra Anwaar, Anum Farooq

引用次数: 0

Preparation, components and application of magnetic nanoparticles: A review 磁性纳米颗粒的制备、组成及应用综述

Journal of Contemporary Pharmacy Practice Pub Date : 2019-07-31 DOI: 10.56770/jcp2019314

Kanza Amjad

引用次数: 0

Preparation of glimepiride mucoadhesive tablets by direct compression method and their in-vitro evaluation 直接压片法制备格列美脲黏合剂及其体外评价

Journal of Contemporary Pharmacy Practice Pub Date : 2019-07-31 DOI: 10.56770/jcp2019311

Anum Akram, A. Kiran, Saddiqa Naeem

{"title":"Preparation of glimepiride mucoadhesive tablets by direct compression method and their in-vitro evaluation","authors":"Anum Akram, A. Kiran, Saddiqa Naeem","doi":"10.56770/jcp2019311","DOIUrl":"https://doi.org/10.56770/jcp2019311","url":null,"abstract":"Objectives: The present investigation is concerned with formulation and evaluation of mucoadhesive buccal tablets containing antidiabetic drug, glimepiride, to circumvent the first pass effect and to improve its bioavailability with reduction in dosing frequency and dose related side effects. Methods: The tablets were prepared by direct compression method. The tablets were tested for weight variation, hardness, surface pH, drug content uniformity, percentage swelling index, bio adhesive strength, exvivo residence time in-vitro drug dissolution study, in-vitro drug release kinetic study, ex-vivo permeation study and stability study. Results: FTIR studies showed no evidence on interactions between drug, polymers, and excipients. The surface pH, bio adhesive strength, ex-vivo residence timeand swelling index of formulation was found to be 6.80±0.02, 36.3±0.04g, 325min and 289.8±0.52%, respectively. The formulation containing 4 mg of glimepiride exhibited 6 h sustained drug release i.e. 93.98±0.8% with desired therapeutic concentration. The drug permeation from the formulation was slow and steady and 3.56 mg of glimepiride could permeate through sheep buccal membrane with a flux of 0.27 mg hr-1 cm-2 . The in-vitro release kinetics studies reveal that all formulations fits well with zero order kinetics and followed non-Fickian diffusion mechanism. Conclusion: Hence, it was concluded that the best formulation was suitable for all the evaluation parameters and can be permeated through human buccal mucosa.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78870054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2